Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Questionnaires

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (2)

Trial Status

Completed2
Suspended1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04306939Suspended

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT01438411Phase 3CompletedPrimary

Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis

NCT01589523Phase 3CompletedPrimary

GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis

Showing all 3 trials

Research Network

Common Treatments

  • Questionnaires1
  • Additional Sample Collections1
  • Glycocholic Acid1
  • Cholic Acid1
  • Venipuncture1

Active Sponsors

  • Children's Hospital Medical Center, Cincinnati1
  • University of Pittsburgh1
  • Mirum Pharmaceuticals, Inc.1

Top Investigators

Related Conditions

  • Constipation Chronic Idiopathic1
  • Chronic Pain1
  • Dyslipidemias1
  • Biliary Cirrhosis1
  • Irritable Bowel Syndrome1

Activity Timeline